1 |
Bianconi M, Jankilevich G, Otero S, Nassif J, Storino C(2007).Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. Gynecol Oncol, 106, 268-71.
DOI
ScienceOn
|
2 |
Bolis G, BonazziC, Landoni F, et al (1988). EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol, 31, 439-44.
DOI
|
3 |
Bower M, Newlands ES, Holden L, et al (1997). EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol, 15, 2636-43.
DOI
|
4 |
Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA (2003). Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol, 91, 552-7.
DOI
|
5 |
Lurain JR (2011). Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol, 204, 11-8.
DOI
ScienceOn
|
6 |
LybolC, Westerdijk K, Sweep FC, et al (2012). Human chorionic gonadotropin (hCG) regression nomograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. Ann Oncol, 23, 2903-06.
DOI
|
7 |
Manopunya M, Suprasert P (2012). Resistant gestational trophoblastic neoplasia patients treated with 5-fluouracil plus actinomycin D. Asian Pac J Cancer Prev, 13, 387-90.
DOI
ScienceOn
|
8 |
Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L(1991). Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol, 98, 550-7.
DOI
|
9 |
Ngan HY, Bender H, Benedet JL, et al (2003). Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet, 83, 175-7.
DOI
|
10 |
Ngan HYS, Kohorn EI, Cole LA, et al (2012). Trophoblastic disease. Int J Gynecol Obstet, 119, 130-6.
DOI
|
11 |
Oranratanaphan S, Lertkhachonsuk R (2014). Treatment of extremely high risk and resistant gestational trophoblastic neoplasia patients in king chulalongkorn memorial hospital. Asian Pac J Cancer Prev, 15, 925-8.
DOI
ScienceOn
|
12 |
Pongsaranantakul S, Kietpeerakool C (2009). Hysterectomy in gestational trophoblastic neoplasia: Chiang Mai University Hospital's experience. Asian Pac J Cancer Prev, 10, 311-4.
|
13 |
van Trommel NE, Ngo Duc H, Massuger LF, et al (2008). Early identification of persistent trophoblastic disease with serum hCG concentration ratios. Int J Gynecol Cancer, 18, 318-23.
DOI
|
14 |
Powles T, Savage PM, Stebbing J, et al (2007). A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer, 96, 732-7.
DOI
|
15 |
Shigematsu T, Kamura T, Saito T, et al (1998). Identification of persistent trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Gynecol Oncol, 71, 376-80.
DOI
|
16 |
van Trommel NE, Massuger LF, Schijf CP, et al (2006). Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol, 24, 52-8.
DOI
|
17 |
WangJ, Short D, Sebire NJ, et al (2008). Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol, 19, 1578-83.
DOI
|